Physician profile
Mark W Sij
NPI 1396705919
$18,404.22
in general payments reported to CMS, 2019-2025
58 companies · $2,354 in 2025
The $2,354 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,238 · 2020: $1,138 · 2021: $1,206 · 2022: $1,536 · 2023: $1,867 · 2024: $2,065 · 2025: $2,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,225 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,224.98 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $7,171.31 | 2019-2025 | |
| Abbvie INC. | $1,875.11 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,507.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $849.18 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $548.95 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $503.26 | 2022-2025 | Veozah |
| Lilly USA, LLC | $497.14 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $475.83 | 2019-2022 | |
| Antares Pharma, INC. | $454.30 | 2020-2025 | Xyosted, Tlando, Nocdurna |
| Otsuka America Pharmaceutical, INC. | $445.49 | 2021-2025 | Rexulti |
| Amgen INC. | $430.29 | 2019-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $340.76 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $325.65 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $251.22 | 2019-2025 | Belsomra, Gardasil 9, Capvaxive |
| Corcept Therapeutics | $193.66 | 2025 | Korlym |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sij listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.